RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 23 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 23

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  3. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  4. Study siteBinzhou Medical University Hospital滨州医学院附属医院YantaiHospital page
  5. Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
  6. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  7. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  8. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  9. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  10. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  11. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  12. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  13. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  14. Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
  15. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  16. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  17. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  18. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  19. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  20. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  21. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  22. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  23. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06962865, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Toxicity due to prior antineoplastic therapy has not recovered to National Cancer Institute Commonly Used Criteria Terminology for Generic Adverse Events, Version 5.0, Grade 0-1;

    Exclusion criterion 10

    Received systemic corticosteroid therapy with >10 mg/day prednisone or other immunosuppressive medications within 2 weeks before randomization;

    Exclusion criterion 15

  3. ECOG PS score 0 or 1;

    Inclusion criterion 7

  4. Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;

    Inclusion criterion 5

  5. At least one measurable lesion according to RECIST v1.1 criteria;

    Inclusion criterion 8

  6. Positive test result for Human Immunodeficiency Virus (HIV) or history of Acquired Immune Deficiency Syndrome (AIDS);

    Exclusion criterion 13

    Active hepatitis B or HCV-positive subjects;

    Exclusion criterion 14

    Other malignant tumor within 5 years before signed the informed consent form;

    Exclusion criterion 16

  7. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose, during which time the female subject is not breastfeeding and the male subject avoids sperm donation.

    Inclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06962865, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in the study and signed the ICF;
  • Male or female, aged 18-75 years;
  • All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/IIIC )or recurrent metastatic NSCLC (stage IV ) and not amendable to curative surgery or radiation as assessed by investigator;
  • For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy;
  • Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;
  • Ability to provide at least 6 sections of tumor tissue specimens for staining and testing;
  • ECOG PS score 0 or 1;
  • At least one measurable lesion according to RECIST v1.1 criteria;
  • Expected survival ≥ 12 weeks;
  • Adequate bone marrow and organ function;
  • Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose, during which time the female subject is not breastfeeding and the male subject avoids sperm donation.

Exclusion Criteria:

  • Subjects with the presence of meningeal metastases, spinal cord compression, or active brain metastases;
  • Received ADC or MET inhibitors;
  • Suffering from refractory nausea and vomiting, chronic gastrointestinal disorders, inability to swallow pharmaceutical preparations, or previous major bowel resection that may prevent adequate absorption, distribution, metabolism, or excretion of oral medications;
  • Subjects with uncontrolled tumor-related pain;
  • Use of an investigational drug or major surgery within 4 weeks before the first dose;
  • Received any live vaccine within 28 days prior to the first dose or plan to be vaccinated during the study;
  • Subjects with uncontrolled or severe cardiovascular disease;
  • Presence of clinically uncontrollable third interstitial effusion;
  • Presence of severe lung disease, including but not limited to active tuberculosis, interstitial lung disease requiring treatment, radiation pneumonitis, etc.
  • Toxicity due to prior antineoplastic therapy has not recovered to National Cancer Institute Commonly Used Criteria Terminology for Generic Adverse Events, Version 5.0, Grade 0-1;
  • Persistent grade ≥2 sensory or motor neuropathy;
  • Active infections requiring systemic IV antibiotic therapy within 7 days before the first dose, allowing routine antimicrobial prophylaxis;
  • Positive test result for Human Immunodeficiency Virus (HIV) or history of Acquired Immune Deficiency Syndrome (AIDS);
  • Active hepatitis B or HCV-positive subjects;
  • Received systemic corticosteroid therapy with >10 mg/day prednisone or other immunosuppressive medications within 2 weeks before randomization;
  • Other malignant tumor within 5 years before signed the informed consent form;
  • Known hypersensitivity or delayed hypersensitivity to RC108, certain components of Furmonertinib or similar drugs or any contraindication to the drug;
  • Poor compliance and unable to complete the study procedures as assessed by investigator;

Quoted from ClinicalTrials.gov, NCT06962865, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06962865, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06962865